Short answer
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an 8-K current report with the SEC on May 22, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors through 2029.
Dianthus Therapeutics, Inc. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Sujay Kango, Anne McGeorge and Jonathan Violin, Ph.D. as Class II directors through 2029
- Jonathan Violin and Sujay Kango received 42,799,946 and 42,739,315 votes, respectively
- Executive compensation approved on an advisory basis, with 41,004,507 votes for and 1,713,043 against
- Deloitte & Touche ratified as independent auditor for fiscal 2026 with 46,298,319 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dianthus Therapeutics, Inc. /DE/ 8-K filings
Get the next DNTH 8-K as it lands
Follow DNTH for push alerts, or ask the research agent what this filing means.